Loading
A phase 3 trial of Ethiodized oil in Hepatocellular carcinoma, run by Stanford University, recorded as terminated on the registry.
Transarterial Chemoembolization Compared With Stereotactic Body Radiation Therapy or Stereotactic Ablative Radiation Therapy in Treating Patients With Residual or Recurrent Liver Cancer Undergone Initial Transarterial Chemoembolization is a phase 3 interventional study registered as NCT02762266 by Stanford University, with 13 participants recorded, started 2016-02-27 and due to reach its primary completion in 2022-12-31. Interventions recorded: Stereotactic Body Radiation Therapy, Transarterial Chemoembolization, embolic agent, lipiodol. Conditions recorded: Child-Pugh Class A, Child-Pugh Class B, Recurrent Hepatocellular Carcinoma.
Linked to the drug Ethiodized oil because the registry names it among its interventions and Hepatocellular carcinoma among its conditions. Registry record only: no result has been read by an editor.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
13 enrolled.
Figures from the ClinicalTrials.gov results section (first posted 2024-03-12), not from a publication
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Number of Participants With a Local Progression Eventprimary | Transarterial Chemoembolization (TACE) | 4 | 0 participants | - | - | link |
| Stereotactic Body Radiation Therapy (SBRT) | 6 | 0 participants |
Shares Ethiodized oil, Intermediate hepatocellular carcinoma (BCLC B), Hepatocellular carcinoma and the tag pipeline.
Shares Ethiodized oil, Intermediate hepatocellular carcinoma (BCLC B), Hepatocellular carcinoma and the tag pipeline.
Shares Intermediate hepatocellular carcinoma (BCLC B), Hepatocellular carcinoma and the tag pipeline.
Shares Intermediate hepatocellular carcinoma (BCLC B), Hepatocellular carcinoma and the tag pipeline.
Shares Intermediate hepatocellular carcinoma (BCLC B), Hepatocellular carcinoma and the tag pipeline.
Shares Intermediate hepatocellular carcinoma (BCLC B), Hepatocellular carcinoma and the tag pipeline.
Shares Hepatocellular carcinoma and the tag pipeline.
Shares Hepatocellular carcinoma and the tag pipeline.